Acorda Therapeutics
Hawthorne, New York, United States
About Acorda Therapeutics
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $151.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2006)
- Ticker: nasdaq:ACOR
- Website: acorda.com
- Phone: (914) 347-4300
Industries & Categories
Biotechnology, Developer Platform, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/acorda-therapeutics-2529051 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.